Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye

Trial Profile

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Tivanisiran (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Acronyms HELIX
  • Sponsors Sylentis
  • Most Recent Events

    • 31 Jan 2019 According to a Sylentis media release, data from the study will be presented at the Annual Congress of the Association for Research in Vision and Ophthalmology, ARVO 2019.
    • 31 Jan 2019 Primary endpoint has not been met. (Change from baseline in Visual Analogue Scale (VAS) scores for eye discomfort/pain as a measurement of SYL1001 effect versus vehicle), according to a Sylentis media release.
    • 31 Jan 2019 Primary endpoint has not been met. (Change from baseline in Corneal Fluorescein Staining (CFS) total scores obtained on the Oxford scale as a measurement of SYL1001 effect versus vehicle), according to a Sylentis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top